Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer (Q35116166)

6 August 2017

1 reference

title

Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer (English)

1 reference

6 August 2017

1 reference

https://api.crossref.org/works/10.1517/14712598.3.1.113

28 December 2023

author name string

Ian Mohr

series ordinal

1

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

full work available at URL

6 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/14712598.3.1.113

1 reference

https://api.crossref.org/works/10.1517/14712598.3.1.113

Expert Opinion on Biological Therapy

28 December 2023

published in

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

113-125

1 reference

Replication-selective microbiological agents: fighting cancer with targeted germ warfare

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Trigeminal Ganglion Infection by Thymidine Kinase-Negative Mutants of Herpes Simplex Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of her

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Inhibition of PACT-mediated activation of PKR by the herpes simplex virus type 1 Us11 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Inhibition of PKR activation by the proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Identification of a lytic-cycle Epstein-Barr virus gene product that can regulate PKR activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Herpes simplex virus turns off the TAP to evade host immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Molecular genetics of herpes simplex virus: Demonstration of regions of obligatory and nonobligatory identity within diploid regions of the genome by sequence replacement and insertion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.113

21 January 2018

9

54

3963

MINETA T

1994

1 reference

https://api.crossref.org/works/10.1517/14712598.3.1.113

28 December 2023

19

57

1502

ANDREANSKY S

1997

1 reference

https://api.crossref.org/works/10.1517/14712598.3.1.113

Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy

28 December 2023

series ordinal

56

1 reference

https://api.crossref.org/works/10.1517/14712598.3.1.113

Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47

28 December 2023

series ordinal

61

1 reference

https://api.crossref.org/works/10.1517/14712598.3.1.113

28 December 2023

Identifiers

1 reference

6 August 2017

1 reference